Kurs
+40,00%
Likviditet
2,88 MSEK
Kalender
| Est. tid* | ||
| 2027-02-23 | 08:00 | Bokslutskommuniké 2026 |
| 2026-11-10 | 08:30 | Kvartalsrapport 2026-Q3 |
| 2026-08-19 | 08:30 | Kvartalsrapport 2026-Q2 |
| 2026-06-24 | N/A | Årsstämma |
| 2026-05-27 | - | Kvartalsrapport 2026-Q1 |
| 2026-05-08 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2026-02-27 | - | Bokslutskommuniké 2025 |
| 2025-11-06 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-13 | - | Kvartalsrapport 2025-Q2 |
| 2025-06-26 | - | Årsstämma |
| 2025-05-28 | - | Kvartalsrapport 2025-Q1 |
| 2025-05-21 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2025-02-28 | - | Bokslutskommuniké 2024 |
| 2025-01-07 | - | Extra Bolagsstämma 2024 |
| 2024-11-06 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-15 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-22 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2024-05-21 | - | Årsstämma |
| 2024-05-07 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2024-01-11 | - | Extra Bolagsstämma 2023 |
| 2023-10-24 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-11 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-24 | - | Kvartalsrapport 2023-Q1 |
| 2023-04-21 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2023-04-20 | - | Årsstämma |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2023-01-09 | - | Extra Bolagsstämma 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-18 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-25 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2022-05-24 | - | Årsstämma |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-12-16 | - | Extra Bolagsstämma 2021 |
| 2021-11-10 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-18 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-10 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2021-05-27 | - | Årsstämma |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-10 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-17 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-28 | - | Extra Bolagsstämma 2020 |
| 2020-06-30 | - | Årsstämma |
| 2020-06-17 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-08 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-16 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-20 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2019-06-19 | - | Årsstämma |
| 2019-05-15 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-09 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-17 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-15 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-29 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2018-03-28 | - | Årsstämma |
| 2018-02-27 | - | Bokslutskommuniké 2017 |
| 2017-11-09 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-17 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-19 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2017-05-18 | - | Årsstämma |
| 2017-05-16 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-27 | - | Bokslutskommuniké 2016 |
| 2016-11-10 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-17 | - | Kvartalsrapport 2016-Q2 |
| 2016-07-22 | - | Extra Bolagsstämma 2016 |
| 2016-05-20 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2016-05-19 | - | Årsstämma |
| 2016-05-17 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-26 | - | Bokslutskommuniké 2015 |
| 2015-11-19 | - | Extra Bolagsstämma 2015 |
| 2015-11-11 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-17 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-08 | - | Kvartalsrapport 2015-Q1 |
| 2015-04-10 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2015-04-09 | - | Årsstämma |
| 2015-02-27 | - | Bokslutskommuniké 2014 |
| 2014-10-15 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-13 | - | Kvartalsrapport 2014-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Peptonic Medical AB (publ) ("Peptonic" or the "Company") today announces that the first shipment under the Company's partnership agreement in the United States has now been dispatched. The delivery represents an important milestone in Peptonic's international expansion and marks the transition from the preparation phase to commercial deliveries under the partnership.
The agreement has been entered into with an established US company specialising in intimate self-care for women during and after menopause and covers the United States, Canada, Mexico and the United Kingdom. Peptonic supplies products that will be marketed and sold under the partner's own well-known brand.
The first order was received in October 2025 and has an initial value of USD 120,000. Since then, Peptonic and the partner have worked together on product design, packaging adaptations and other preparations for delivery.
"The completion and dispatch of the first order is a significant step for Peptonic and a tangible result of the work carried out together with our partner. The delivery demonstrates our ability to turn strategic international partnerships into commercial operations and provides an important foundation for continued growth in the US market and the other markets covered by the agreement," says Daniel Rudeklint, interim CEO of Peptonic Medical.
The Company's growth strategy is based on geographic expansion, strategic partnerships and product development. By combining Peptonic's product development and medical technology expertise with the partner's established market presence, the collaboration creates opportunities to reach more women with effective, gentle and science-based intimate self-care products.
For further information, please contact:
Daniel Rudeklint, interim CEO, Peptonic Medical AB
Email: daniel.rudeklint@peptonicmedical.se
Telephone: +46 73 158 02 73
About Peptonic Medical AB
Peptonic Medical AB (publ) is a Swedish medical technology company that develops and sells clinically proven self-care products for women's intimate health. Under the VagiVital and Vernivia brands, the Company offers an over-the-counter portfolio of effective and gentle products that help women understand, treat and prevent common intimate health conditions. Peptonic's growth strategy is based on geographic expansion, particularly in the United States and Europe, and on continuously strengthening its product portfolio through in-house product development and strategic acquisitions.